ADGM
What one share of Adagio Medical Holdings holds
Surgical and Medical Instruments and Apparatus
We are a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with our novel, proprietary, catheter-based Ultra-Low Temperature Ablation (“ULTA”) technology, formerly known as Ultra-Low Temperature Cryoablation (“ULTC”) technology.
Adagio Medical Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.28 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.83 |
| Cash and investments | $0.35 |
| Debt | $1.12 |
| Book value | −$0.02 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.39 | −$48.16 | $0.44 | −$34.20 | $0.00 | −$169.28 |
| 2025 | $0.00 | −$1.51 | $0.02 | −$1.17 | — | $0.56 |